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ABSTRACT
Introduction Pregnant women with gestational diabetes 
mellitus (GDM) are at risk of adverse outcomes, including 
gestational hypertension, pre- eclampsia, and preterm 
delivery. This study was undertaken to determine if 
apolipoprotein (apo) levels differed between pregnant 
women with and without GDM and if they were associated 
with adverse pregnancy outcome.
Research design and methods Pregnant women (46 
women with GDM and 26 women without diabetes (ND)) in 
their second trimester were enrolled in the study. Plasma 
apos were measured and correlated to demographic, 
biochemical, and pregnancy outcome data.
Results apoA2, apoC1, apoC3 and apoE were lower 
in women with GDM compared with control women 
(p=0.0019, p=0.0031, p=0.0002 and p=0.015, 
respectively). apoA1, apoB, apoD, apoH, and apoJ levels 
did not differ between control women and women with 
GDM. Pearson bivariate analysis revealed significant 
correlations between gestational age at delivery and apoA2 
for women with GDM and control women, and between 
apoA2 and apoC3 concentrations and C reactive protein 
(CRP) as a measure of inflammation for the whole group.
Conclusions Apoproteins apoA2, apoC1, apoC3 and apoE 
are decreased in women with GDM and may have a role in 
inflammation, as apoA2 and C3 correlated with CRP. The 
fact that apoA2 correlated with gestational age at delivery 
in both control women and women with GDM raises the 
hypothesis that apoA2 may be used as a biomarker of 
premature delivery, and this warrants further investigation.
INTRODUCTION
Gestational diabetes mellitus (GDM) is the 
most frequent pregnancy- associated meta-
bolic disorder occurring in ~7% of all preg-
nancies1 and is usually detected towards 
the end of the second trimester.2 GDM 
is associated with adverse maternal and 
fetal outcomes, including pre- eclampsia, 
macrosomia, neonatal hypoglycemia and 
hyperbilirubinemia, during the perinatal 
period.3 Women with a history of GDM are 
at increased risk of subsequent development 
of cardiovascular disease (CVD)4 and have 
greater than seven fold increased risk of 
the development of type 2 diabetes mellitus 
(T2D).1 5
Pregnancy is accompanied by increased 
insulin resistance, a physiological, metabolic 
adaptation to accommodate the nutritional 
demands of the fetus.6 Insulin resistance 
is typically compensated for by an adap-
tive increase in glucose- stimulated insulin 
release,7 together with an adaptive increase 
in beta- cell mass.8 The insulin requirements 
in overweight or obese pregnant women are 
amplified, and when demand outstrips secre-
tory capacity, gestational diabetes ensues.9 
The underlying mechanisms driving insulin 
resistance in pregnancy are complex and 
are not fully understood; however, placental 
hormones, obesity, inactivity, poor diet, and 
Significance of this study
What is already known about this subject?
 ► Pregnant women with gestational diabetes are at 
risk of adverse outcomes, including hypertension, 
pre- eclampsia, and pre- term delivery, and apolipo-
proteins (apos) may be mechanistically involved in 
the pathophysiology of these adverse outcomes.
What are the new findings?
 ► apoA2, apoC1, apoC3 and apoE levels were reduced 
in women with gestational diabetes, while apoA2 
correlated with gestational age at delivery in preg-
nant women with, as well as without, gestational 
diabetes.
 ► apoA2 correlated with gestational age at delivery 
in pregnant women with, as well as without, ges-
tational diabetes and therefore may be useful as a 
biomarker of premature delivery.
How might these results change the focus of 
research or clinical practice?
 ► Decreased levels of apoA2, apoC1, apoC3 and apoE 
may promote inflammation in gestational diabetes, 
while apoA2 may serve as a useful biomarker of pre-
mature delivery.
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genetic/epigenetic factors are known contributing 
factors.10
Risk factors for GDM include older maternal age, 
multiparity, ethnicity, family history of diabetes, weight 
gain during pregnancy11 and pregravid overweight or 
obesity.12 13 The identification of biochemical markers 
that might reliably predict the development of GDM and 
GDM- related maternal or fetal complications would have 
practical diagnostic and therapeutic utility. In addition, 
such markers may assist in understanding the biochem-
ical pathways in GDM that are distinct from, or common 
to, those with T2D.
Apolipoproteins (apos), through their amphipathic 
properties, enable the transport of hydrophobic lipids 
in aqueous body fluids.14 To accomplish this, apos, 
together with other amphipathic molecules such as phos-
pholipids, surround the hydrophobic lipid molecules to 
create water- soluble lipoproteins. Besides solubilizing 
lipids and stabilizing lipoprotein structure, apos also 
contribute to lipoprotein uptake and clearance through 
interaction with lipoprotein receptors and lipid transport 
proteins and act as enzyme cofactors during lipoprotein 
metabolism.15
The lipid and apo changes that occur during preg-
nancy have long been recognized16 and enable a contin-
uous supply of nutrients to reach the fetus.6 Most notable 
is the elevation of serum triglycerides, and, to a lesser 
extent, cholesterol17 (apoA1 and apoB) also increases 
with the progression of pregnancy.16 18 Disturbances in 
lipid profiles in pregnancy, however, increase CVD risk 
and result in adverse maternal and fetal outcomes19 20 
such as pre- eclampsia,20 21 GDM,22 23 fetal growth restric-
tion (FGR) and premature delivery.19 24
While apos have emerged as screening tools for cardio-
vascular risk assessment and have proven to be even 
more predictive biomarkers than serum lipids,25 26 they 
also have potential as biomarkers for adverse pregnancy 
outcomes.27 28 In the setting of FGR, apoB100 levels were 
reduced in maternal serum.28 A high level of apoA1 
in maternal serum was associated with early miscar-
riage,29 and an increase in apoA2 has been associated 
with gestational age.30 Elevations of apoE, apoB:apoA1 
ratio and triglycerides are associated with a higher risk 
of pre- eclampsia,31 which is associated with increased 
cardiovascular risk in later life.32 33 However, in pregnant 
women, serum apoA1 was shown not to be associated 
with insulin resistance or GDM.34 More recently, post-
partum apo levels, specifically elevated apoC3 and the 
ratios of apoC3:apoA1, apoC3:apoA2, apoC3:apoC2, and 
apoC3:apoE, have been shown to represent independent 
risk factors for the development of T2D in women who 
have GDM.35
This study aimed to determine whether serum apo 
levels in a cohort of second trimester pregnant women 
differed in those with and without GDM, and if they were 
associated with inflammation and/or adverse pregnancy 
outcome.
RESEARCH DESIGN AND METHODS
Study design
This was a cross- sectional study in 68 pregnant women (42 
women with GDM and 26 women without diabetes (ND)) 
who were recruited during their second trimester at the 
antenatal clinic at the Women’s Wellness and Research 
Center of Hamad Medical Corporation, Doha, Qatar, 
from 2016 to 2017. Demographics, anthropometrics, 
and medical history data were collected, including age, 
ethnicity, socioeconomic background, vital signs, height, 
weight, menstrual cycle, the period of infertility, medica-
tions, complications, comorbidities, and family medical 
history. All pregnant women were screened in the first 
antenatal care visit using fasting blood glucose (FBG). If 
the FBG at the first visit was <5.1 mmol/L (92 mg/dL), 
75 g oral glucose tolerance test (OGTT) was performed at 
24 weeks' gestation. The WHO criteria (FBG≥5.1 mmol/L 
(92 mg/dL), 1- hour post- OGTT≥10.0 mmol/L (180 mg/
dL) or 2- hour post- OGTT≥8.5 mmol/L (153 mg/dL)) 
were used to diagnose GDM. Patients with GDM were 
enrolled as soon as the diagnosis was confirmed (within 
1 week of the OGTT and before 25 weeks’ gestation), 
when the blood sample was drawn. Patients with GDM 
were started on a nutritional therapy diet for 2 weeks 
to achieve an FBG of ≤5.3 mmol/L (95 mg/dL) and 
the 2- hour postprandial glucose being ≤6.8 mmol/L 
(120 mg/dL) in ≥80% of the readings. If more than 
20% of the readings were above target, then metformin 
therapy was implemented and increased incrementally to 
a maximum of 2 g/day, followed by insulin supplementa-
tion when glucose targets were not achieved.
Collection and analysis of blood samples
Blood samples were collected and immediately processed 
and stored frozen at −80°C pending analysis, as previ-
ously reported.36 “The thyroid- stimulating hormone, 
insulin and C reactive protein (CRP) were measured in 
the Chemistry Laboratory at Hamad Medical Corpora-
tion, Doha, Qatar, and measured by an immunometric 
assay with fluorescence detection on the DPC Immu-
lite 2000 analyzer using the manufacturer’s recom-
mended protocol. Total cholesterol, triglycerides, and 
high- density lipoprotein (HDL) cholesterol levels were 
measured enzymatically using a Synchron LX20 analyzer 
(Beckman- Coulter, High Wycombe, UK). Low- density 
lipoprotein (LDL) cholesterol was calculated using the 
Friedewald equation. Serum insulin was assayed using a 
competitive chemiluminescent immunoassay performed 
on the manufacturer’s DPC Immulite 2000 analyzer 
(Euro/DPC, Llanberis, UK). The analytical sensitivity 
of the insulin assay was 2μU/mL; the coefficient of vari-
ation was 6%; and there was no stated cross- reactivity 
with proinsulin. Plasma glucose was measured using a 
Synchron LX 20 analyzer (Beckman- Coulter), using the 
manufacturer’s recommended protocol. The coefficient 
of variation for the assay was 1.2% at a mean glucose 
value of 5.3 mmol/L during the study period. Pregnancy 
outcomes of gestational age at delivery, birth weight, 
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maternal weight, blood pressure, and fetal outcome were 
recorded and collated with the apo profile for all subjects 
who participated in the study.
Apolipoproteins assay protocol
apos were measured from EDTA plasma samples. apo levels 
were determined using the Bio- Plex Pro Human Apoli-
poprotein 10- Plex Assay Panel (Cat # 12003081; Bio- Rad, 
Hertfordshire, UK). This is a sensitive magnetic bead- based 
multiplexing protein panel that measures quantitative 
levels of these proteins simultaneously in plasma. Apopro-
tein levels in the samples were quantitated by the 5PL (five 
parameters) logistic regression algorithms that come with 
the Bioplex manager six software, which were used for 
quantification of samples in reference to standards. The 
measurements were run on Bioplex-200 (Bio- Rad) instru-
ment. The plasma samples were diluted 50 000 times to 
get the apoprotein levels within the range of the standard 
curve. The sensitivity, working range and assay precision 
for different apos were as follows: apoA1, 140–0.093 ng/
mL, intra- assay coefficient of variation (CV) 6% and inter-
assay CV 9%; apoA2, 30–0.045 ng/mL, intra- assay CV 5% 
and interassay CV 6%; apoB, 300–0.38 ng/mL, intra- assay 
CV 10% and interassay CV 15%; apoC1, 17–0.024 ng/
mL, intra- assay CV 2% and interassay CV 5%; apoC3, 
33–0.029 ng/mL, intra- assay CV 4% and interassay CV 5%; 
apoD, 25–0.070 ng/mL, intra- assay CV 4% and interassay 
CV 6%; apoE, 12–0.019 ng/mL, intra- assay CV 3% and 
interassay CV 12%; apoH, 210–0.34 ng/mL, intra- assay CV 
3% and inter- assay CV 4%; apoJ, 170–0.14 ng/mL, intra- 
assay CV 7% and interassay CV 7%; and CRP, 12–0.013 ng/
mL, intra- assay CV 4% and interassay CV 6%.
Statistical analysis
Based on a study on apo levels that showed significant differ-
ences of apoA2 and apoC levels in metabolic syndrome,37 a 
population sample size of 38 patients was calculated, giving 
80% power to detect a difference with a two- sided alpha 
error of 0.05 (nQuery, Statsol, USA). Descriptive statistics 
and means±SDs were calculated for all continuous variables 
in the study. Student’s t- test was used to compare mean 
differences between control and GDM groups. Pearson 
rank correlation was performed to understand the associ-
ations between apos and demographic variables. All statis-
tical analysis was done using statistical analysis SPSS V.26 
software. A statistical significance level (p value) of <0.05 
was considered as significant.
RESULTS
Demographics
General characteristics of participants
Seventy- two young (31.5±5.5 years) overweight/obese 
(32.2±7.1 kg/m2) pregnant women were included in 
this study (46 women with GDM and 26 control women 
ND). The women with GDM were older than the control 
women (32.8±5.4 vs 29.1±4.9 years, women with GDM 
vs control women, p<0.01). BMI was matched in both 
groups (33.2±6.6 vs 30.2±7.8 kg/m2, women with GDM 
vs control women, p=not significant (ns)). Systolic and 
diastolic blood pressures were comparable in both 
groups. GDM was diagnosed at 20.5±5.1 weeks’ gestation. 
By definition, fasting glucose was elevated in the GDM 
group (5.4±0.9 vs 4.6±0.2 mmol/L, women with GDM vs 
control women, p=0.029). HbA1c did not differ signifi-
cantly between groups (5.2±0.4 vs 5.1%±0.4%, women 
with GDM vs control women, p=ns), reflecting the recent 
onset of elevated plasma glucose in the GDM women. 
Biochemical profile, most notably, lipids (cholesterol, 
triglycerides, HDL and LDL), did not differ between 
groups, neither was there a difference in gestational age 
at delivery between groups (38.2±1.5 vs 38.4±2.1 weeks, 
women with GDM vs control women, p=ns) (table 1). 
Out of the 72 pregnancies, 70 resulted in live births (two 
fetuses from the GDM group died in utero). Of note, the 
high rate of fetal demise reported in this study is entirely 
due to the sample size being small and a consequence 
of rare events, such as severe congenital abnormalities. 
From the same population, we have previously reported 
on two cohorts of women with gestational diabetes; in 
the first, the rate of fetal demise was 0.25%,12 and in the 
second larger cohort, the rate of fetal demise was 0.1%.38
Apolipoproteins
apoA2 was higher in control women compared with 
women with GDM (268.7±39.4 vs 241.0±30.5 μg/mL, 
control women vs women with GDM, p=0.002). Likewise, 
apoC1, apoC3 and apoE were higher in control women 
compared with women with GDM (apoC1: 300.7±50.6 vs 
260.3±53.8 μg/mL, control women vs women with GDM, 
p=0.003; apoC3: 77.5±28.7 vs 56.5±14.6 μg/mL, control 
women vs women with GDM, p=0.0002; apoE: 18.6±7.0 
vs 15.2±4.2 μg/mL, control women vs women with GDM, 
p=0.015). The CRP level was higher in the GDM group 
(117±93 vs 57±52 μg/mL, women with GDM vs control 
women, p=0.003). apoA1, apoB, apoD, apoH and apoJ 
levels did not differ between control women and women 
with GDM (table 2).
Because the maternal age and Body Mass Index (BMI) 
of the women with GDM and the control group were not 
comparable, we performed a linear regression analysis 
after adjusting for age and BMI as confounding factors. 
The analysis showed that apoA2 (p=0.019), apoC1 
(p=0.005), apoC3 (p<0.0001) and apoE (p=0.042) still 
remained significantly different between the women with 
GDM and the control group, suggesting that age and 
BMI did not impact the levels of these proteins in our 
study subjects.
For the combined group (control women and women 
with GDM inclusive), we used Pearson bivariate analysis 
to examine for correlation between apoprotein levels 
and demographic, clinical and biochemical data. A posi-
tive significant correlation was found between apoA2 and 
gestational age delivery for the whole group (r=0.390, 
p=0.001; table 3) that was also observed individually 
for both women with GDM (r=0.323, p<0.04) and for 
control women (r=0.46, p<0.02; data not shown). For 
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the whole group, apoC3 correlated with the gestational 
age at GDM diagnosis (r=0.330, p=0.006). Significant 
negative correlations were observed between CRP levels 
with apoA2 (r=−0.268, p=0.027) and apoC3 (r=−0.247, 
p=0.042) (table 3) for the whole group, but CRP did not 
correlate with either apoA2 or apoC3 in women with 
GDM or in control women individually.
Several significant correlations were found between 
several apos, which reflect their coordinate regulation 
and physiological role in lipid metabolism (table 3). The 
Table 1 Demographic data of the women with GDM (n=46) and control (n=26) women
Control women Women with GDM t- Test
Mean SD Mean SD P value
Maternal characteristics
  Age (years) 29.1 4.9 32.8 5.4 0.006
  Prepregnancy weight (kg) 57.2 13.2 62.5 11.9 0.42
  Body Mass Index (kg/m2) 30.2 7.8 33.2 6.6 0.09
  SBP baseline (mm Hg) 109 11 112 12 0.41
  DBP baseline (mm Hg) 65 8 63 7 0.17
  Second- term SBP (mm/Hg) 120 11 120 10 0.96
  second- term DBP (mm Hg) 72 7 72 9 0.75
  Maternal weight at delivery (kg) 82 16.2 84.9 14 0.44
Biochemical variables
  Fasting glucose (mmol/L) 4.6 0.2 5.4 0.9 0.03
  Insulin result (IU/L) 0.3 0.3 0.6 0.9 0.14
  Glycated hemoglobin (%) 5.1 0.4 5.2 0.4 0.24
  Thyroid- stimulating hormone (mU/L) 2.5 3.2 2.2 3.4 0.8
  Alanine aminotransferase (U/l) 12.9 10 17.4 11.7 0.11
  Aspartate transaminase (U/L) 16.6 5.8 21.1 16.9 0.2
  Cholesterol (mmol/L) 5 1.1 4.9 1.1 0.65
  Triglycerides (mmol/L) 1.2 0.6 1.4 0.8 0.41
  High- density lipoprotein (mmol/L) 1.5 0.4 1.4 0.3 0.15
  Low- density lipoprotein (mmol/L) 3 0.9 3 0.9 0.95
Newborn characteristics
  Gestational age at delivery (weeks) 38.4 2.1 38.2 1.5 0.65
  Birth weight (g) 3061 509 3037 596 0.875
DBP, diastolic blood pressure; GDM, gestational diabetes mellitus; SBP, systolic blood pressure.
Table 2 apo levels in women with GDM and control women
Control women Women with GDM t- Test
Mean SD Mean SD P value
apoA1 (µg/mL) 1838.0 449.7 1704.0 289.9 0.14
apoA2 (µg/mL) 268.7 39.4 241.0 30.5 0.002
apoB (µg/mL) 1213.4 364.6 1352.5 341.7 0.12
apoC1 (µg/mL) 300.7 50.6 260.3 53.8 0.003
apoC3 (µg/mL) 77.5 28.7 56.5 14.6 0.0002
apoD (µg/mL) 45.4 26.4 44.5 14.8 0.86
apoE (µg/mL) 18.6 7.0 15.2 4.2 0.02
apoH (µg/mL) 583.8 306.5 620.5 336.1 0.65
apoJ (µg/mL) 157.3 102.7 183.9 117.3 0.34
CRP (µg/mL) 57.3 51.9 117.1 93.0 0.003
apo, apolipoprotein; CRP, C reactive potein; GDM, gestational diabetes mellitus.
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close association between the different apos can be seen 
in the STRING analysis shown in figure 1.
DISCUSSION
The results of this study revealed lower apo levels for 
apoA2, apoC1, apoC3 and apoE in women with GDM 
versus control women and a significant correlation 
between apoA2 and gestational age was seen for both 
women with GDM and control women. apoA2 and apoC3 
correlated significantly with CRP for the whole group.
Little is known about the role of apoA2 in pregnancy. 
apoA2 levels were unchanged in normal pregnancy 
complicated by pre- eclampsia39; however, modified 
apoA2 isoforms were reported to be significantly elevated 
in plasma from mothers who delivered prematurely 
relative to term controls,30 in accord with the findings 
reported for both the women with GDM and the control 
women here. This strong correlation seen between apoA2 
in both control women and women with GDM raises the 
possibility that apoA2 may be a biomarker for premature 
delivery.
apoC1 is involved in lipid transport and metabolism.40 
apoC1 is the only identified inhibitor of cholesteryl ester 
transfer protein,41 a function that is impaired in patients 
with dyslipidemia and coronary artery disease.42 Results 
of several studies, taken together, indicate that apoC1 
plays a role in the development of diabetes.40 The role 
of apoC1 both in GDM and in pregnancy generally is 
unclear, though the results of this study suggest that its 
role in GDM needs clarification.
apoC3 regulates triglyceride- rich lipoprotein metab-
olism.43 apoC3 overexpression contributes to the devel-
opment of atherosclerosis.44 In patients with T2D, raised 
apoC3 levels are associated with raised triglycerides and 
coronary artery calcification.45 apoC3 transgenic mice 
with abnormal lipid metabolism showed gestational 
hypertension in an animal model,46 and a raised plasma 
apoC3:apoC2 ratio was predictive of pre- eclampsia in 
later pregnancy,47 suggesting an important role in preg-
nancy, perhaps through inflammation,48 that would be 
in accord with its association with CRP seen here. apoC3 
was found to correlate with gestational age at the time 
that GDM was diagnosed, suggesting that apoC3 levels 
may predict GDM. It was anticipated that apoC3 would 
be associated with blood pressure as noted previously,47 
but that was not seen. There were no other correlations 
of the apos and pregnancy outcomes, and the negative 
results seen for apoA1, apoC2 and apoC3 were in accord 
with others who showed no correlation with gestational 
age.30
apoE is an important component of the reverse choles-
terol transport pathway, essential for the uptake and 
clearance of atherogenic lipoproteins.49 apoE modifies 
inflammatory responses in foam cells and therefore plays 
an important role in atherosclerosis.50 apoE polymor-
phisms have been associated with recurrent pregnancy 
loss, though the role of apoE during gestation is unclear.51
The close association of the apoproteins with each 
other was seen in the results found here and exemplified 
by the STRING analysis that was performed and shown 
in figure 1. However, of particular interest in this study 
was the association of apoA2, apoC1, apoC3 and apoE 
that appear to be evolutionarily connected with apoA1, 
though no association with GDM was found in the latter.52
While most work on apos and inflammation has been 
done in the context of CVD,53 the negative correlation of 
apoA2 and apoC3 with CRP seen here suggests a more 
generalizable relationship between apos and inflamma-
tion. The association of apoC3 with CRP would indicate 
that inflammation may be driving the insulin resistance 
and hence the elevation in CRP in women with GDM; 
however, the converse could be the case as noted earlier,54 
and the role of apoproteins in women with GDM requires 
clarification.
The study limitations include relatively small numbers 
of pregnant women in each group, which may have 
prevented the detection of differences between groups. 
As a cross- sectional study with serum analysis at a single 
time point during the second trimester, dynamic changes 
in apo levels throughout pregnancy could not be assessed. 
While likely generalizable, these findings should be 
confirmed in other ethnic populations.
Figure 1 Search tool for retrieval of interacting genes 
(STRING) analysis (https://stringdb.org/) of human apoC1 
protein–protein interaction network. apoC1 interacts with 
apoA2, apoC3 and apoE, all of which were found to differ 
between GDM and control women. STRING analysis 
illustrates the closest partners, based on evidence: magenta: 
experimentally determined; black: coexpression; blue: 
from curated databases. We acknowledge the use of the 
STRING technology that is freely available under a 'Creative 
commons by 4.0' license (https://string-db.org/cgi/access.
pl?footer_active_subpage=licensing). APO, apolipoprotein; 
CETP, cholesteryl ester transfer protein; GDM, gestational 
diabetes mellitus; LCAT, lecithin–cholesterol acyltransferase; 
VLDLR, very low- density lipoprotein receptor.
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In conclusion, apoA2, apoC1, apoC3 and apoE were 
lower in women with GDM and may have a role in inflam-
mation, as both apoA2 and C3 correlated with CRP. 
apoC3 correlated with gestational age at GDM diagnosis, 
and apoA2 correlated with early gestational delivery in 
both women with GDM and control women, warranting 
its further investigation as a biomarker of premature 
delivery.
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